MAIA Biotechnology, Inc.
MAIA US5526411021
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Annual Performance 1
| 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|
| -21% | -67% | 66% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Smith Stan |
1.30 USD |
19,230 Bought |
24,999 USD |
01/10/2025 | 01/10/2025 |
| Smith Stan |
1.50 USD |
33,333 Bought |
50,000 USD |
03/06/2025 | 03/06/2025 |
| Smith Stan |
1.50 USD |
33,333 Bought |
50,000 USD |
03/06/2025 | 03/06/2025 |
| Smith Stan |
1.50 USD |
66,666 Bought |
99,999 USD |
08/05/2025 | 08/05/2025 |
| Smith Stan |
1.50 USD |
66,666 Bought |
99,999 USD |
08/05/2025 | 08/05/2025 |
| Guerrero Ramiro |
1.50 USD |
20,000 Bought |
30,000 USD |
08/05/2025 | 08/05/2025 |
| Guerrero Ramiro |
1.50 USD |
20,000 Bought |
30,000 USD |
08/05/2025 | 08/05/2025 |
| Guerrero Ramiro |
1.50 USD |
33,333 Bought |
50,000 USD |
03/03/2025 | 03/03/2025 |
| Smith Stan |
1.50 USD |
25,000 Bought |
37,500 USD |
03/03/2025 | 03/03/2025 |
| Smith Stan |
1.50 USD |
50,000 Bought |
75,000 USD |
24/02/2025 | 24/02/2025 |